

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-35. (cancelled)

1 36. (New) A method of inhibiting an inflammatory response in a mammal,
2 the method comprising administering to the mammal a compound that inhibits the activity of a
3 core 2 GLcNAc transferase, thereby inhibiting the inflammatory response in the mammal.

1 37. (New) The method of claim 36, wherein the compound is a sugar
2 nucleotide.

1 38. (New) The method of claim 36, wherein the compound is an analog of an
2 acceptor substrate of the core 2 GLcNAc transferase.

1 39. (New) The method of claim 36, wherein the inflammatory response is
2 associated with an acute inflammatory disease.

1 40. (New) The method of claim 39, wherein the acute inflammatory disease
2 selected from the group consisting of appendicitis, tonsillitis, delayed hypersensitivity reactions,
3 inflammation due to sepsis, cutaneous inflammation and ischemic reperfusion injury.

1 41. (New) The method of claim 36, wherein the inflammatory response is
2 associated with a chronic inflammatory disease.

1 42. (New) The method of claim 41, wherein the chronic inflammatory disease
2 is rheumatoid arthritis.

1 43. (New) The method of claim 36, wherein the compound is administered
2 parenterally.

1 44. (New) The method of claim 36, wherein the inhibition of activity of the
2 core 2 GLcNAc transferase is determined by measuring core 2 GLcNAc transferase activity in a
3 sample from the patient.

1 45. (New) The method of claim 36, wherein the inhibition of activity of the
2 core 2 GLcNAc transferase is determined by measuring the amount of core 2 glycans in a sample
3 from the patient.

1 46. (New) A method of modulating binding of a first myeloid cell to an
2 endothelial cell or to a second myeloid cell, the method comprising contacting the first myeloid
3 cell with a compound that binds to, or modulates the synthesis of, a core 2 oligosaccharide.

1 47. (New) The method of claim 46, wherein the first myeloid cell is present
2 in a mammal.

1 48. (New) The method of claim 46, wherein the first myeloid cell is selected
2 from the group consisting of neutrophils, eosinophils, monocytes, and granulocytes.

1 49. (New) The method of claim 46, wherein the binding of the first myeloid
2 cell to the endothelial cell or to the second myeloid cell is inhibited.